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Anxiety and panic are the most common adverse effects of cannabis intoxication; reactions potentiated by stress. Data suggest that
cannabinoid (CB1) receptor modulation of amygdalar activity contributes to these phenomena. Using Fos as a marker, we tested the
hypothesis that environmental stress and CB1 cannabinoid receptor activity interact in the regulation of amygdalar activation in male mice.
Both 30min of restraint and CB1 receptor agonist treatment (D
9-tetrahydrocannabinol (2.5mg/kg) or CP55940 (0.3mg/kg); by i.p.
injection) produced barely detectable increases in Fos expression within the central amygdala (CeA). However, the combination of
restraint and CB1 agonist administration produced robust Fos induction within the CeA, indicating a synergistic interaction between
environmental stress and CB1 receptor activation. An inhibitor of endocannabinoid transport, AM404 (10mg/kg), produced an additive
interaction with restraint within the CeA. In contrast, fatty acid amide hydrolase (FAAH) inhibitor-treated mice (URB597, 1mg/kg) and
FAAH
 /  mice did not exhibit any differences in amygdalar activation in response to restraint compared to control mice. In the
basolateral (BLA) and medial amygdala, restraint stress produced a low level of Fos induction, which was unaffected by cannabinoid
treatment. Interestingly, the CB1 receptor antagonist SR141716 dose-dependently increased Fos expression in the BLA and CeA. These
data suggest the CeA is an important neural substrate subserving the interactions between cannabinoids and environmental stress, and
could be relevant to understanding the context-dependent emotional and affective changes induced by marijuana intoxication and the
role of endocannabinoid signaling in the modulation of amygdalar activity.
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INTRODUCTION
The subjective effects of cannabis intoxication include
euphoria, relaxation and impaired cognition, and, under
certain circumstances, anxiety, panic, and overt psychosis
(Abel, 1971; Szuster et al, 1988; Adams and Martin, 1996;
Thomas, 1996; Degenhardt et al, 2001). Data suggest that
some of these effects are dependent upon environmental
context, basal levels of anxiety, and previous drug
experience (Jones, 1971; Carlin et al, 1972; Szuster et al,
1988). In particular, adverse reactions such as anxiety and
panic induced by cannabis are more common in drug-naı ¨ve
subjects and in novel or stressful environmental situations.
For example, D
9-tetrahydrocannabinol (THC)-induced an-
xiety reactions in humans are potentiated by oral surgery
procedures and during cognitive tasks accompanied by
experimenter harassment (Gregg et al, 1976; Naliboff et al,
1976). Consistent with these observations, the most
common reasons given for cessation of cannabis use are
anxiety and panic reactions (symptoms reported in as much
as 20% of subjects); however, the most common reasons
given for continued cannabis use in long-term users are
relaxation and reduced tension (Szuster et al, 1988; Thomas,
1996; Reilly et al, 1998). These data suggest that appropriate
modulation of cannabinoid systems could have anxiolytic
actions in humans. Although adverse anxiety and panic
reactions severely limit the clinical utility of direct CB1
agonists, recent preclinical data suggest that pharmacolo-
gical modulation of endogenous cannabinoid (eCB) systems
could represent a novel approach to the treatment of
anxiety-related neuropsychiatric disorders (Marsicano et al,
2002; Kathuria et al, 2003).
Consistent with human data, dose- and environment-
dependent effects of cannabinoids have also been reported
in the animal literature. Low doses of THC and synthetic
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rodents, whereas higher doses produce anxiety-like beha-
viors and activation of the hypothalamic-pituitary-adreno-
cortical axis (Manzanares et al, 1999; Giuliani et al, 2000;
Berrendero and Maldonado, 2002; Marin et al, 2003). In
addition, the expression of anxiety-like behaviors and
associated biochemical alterations induced by THC are
facilitated by exposure to novel or stressful environments
(Ng et al, 1973; MacLean and Littleton, 1977). Taken
together, these data suggest strong interactions among
cannabinoids, anxiety, and environmental stress; however,
the neural substrates subserving these interactions have
only begun to be explored (MacLean and Littleton, 1977;
Onaivi et al, 1995; McGregor et al, 1998).
Anatomical, cellular, and functional evidence suggests
that the amygdala plays a key role in emotional and affective
changes experienced during cannabis intoxication, and
could contribute to the interaction of cannabinoids with
environmental stressors. The basolateral complex of the
amygdala (BLA) receives and integrates sensory informa-
tion from the cortex and thalamus, and under appropriate
circumstances can activate specific output structures
including the central nucleus of the amygdala (CeA) (Davis,
2002; Sah et al, 2003). Projections from the CeA to
hypothalamic and brainstem structures contribute to the
behavioral and physiological activation associated with
emotionally salient environmental stimuli (Davis, 2002).
High levels of CB1 cannabinoid receptors are expressed by a
subset of cholecystokinin (CCK)-positive GABAergic inter-
neurons within the BLA (McDonald and Mascagni, 2001).
CB1 receptors are also expressed by BLA pyramidal
neurons, but at lower levels (McDonald and Mascagni,
2001). CB1 receptors have also been reported within the
CeA, but neurochemical characterization within this region
is lacking (Matsuda et al, 1993; Tsou et al, 1998). Activation
of CB1 receptors within the BLA decreases both GABAergic
and glutamatergic neurotransmission via presynaptic in-
hibition of neurotransmitter release (Katona et al, 2001;
Azad et al, 2003). However, CB1 activation in the CeA does
not modulate GABAergic transmission, and effects on
glutamatergic transmission have not been studied (Katona
et al, 2001). Similarly, no data regarding the cellular effects
of cannabinoids within the medial amygdala (MeA) are
available. Functionally, it has been shown that systemic
administration of CB1 agonists induces robust Fos expres-
sion within the CeA (McGregor et al, 1998; Arnold et al,
2001), and direct injection of THC into this region produces
anxiety-like responses in mice (Onaivi et al, 1995).
Although complex, the role of CB1 receptor activation in
the modulation of amygdalar circuitry provides a frame-
work from which predictions can be made regarding the
mechanisms by which cannabinoids affect emotional
processes.
Based on the prominent role of CB1 receptor activity in
the inhibition of GABAergic transmission within the BLA,
Katona et al (2001) have proposed that activation of CB1
receptors results in increased activity of BLA principal
projection neurons, which initiates an increase in the
activity of their efferent targets, including CeA neurons.
They hypothesize that this mechanism could account for the
anxiety-like behaviors and robust CeA activation associated
with cannabinoid administration. Since the activity of BLA
pyramidal neurons is tightly regulated by local GABAergic
transmission (Pare et al, 2003; Quirk and Gehlert, 2003),
and CB1 agonists attenuate GABAergic neurotransmission,
an extension of this hypothesis is that cannabinoids
effectively reduce the threshold at which salient sensory
stimuli activate the BLA–CeA pathway (Katona et al, 2001).
Such a mechanism could account for the finding that
subthreshold environmental stress or even normally neutral
stimuli can acquire emotional or affective salience during
cannabis intoxication.
In this study, we tested the hypothesis that cannabinoid
administration modulates amygdalar activation in response
to mild environmental stress. Our results indicate that
cannabinoid agonists can interact synergistically with
salient environmental stimuli to facilitate CeA activation.
These data support a role for the CeA in the interactions
between cannabinoids and stress. In addition, these findings
shed light on the role of eCB signaling in the modulation of
amygdalar activity in vivo and could have implications for
the development of eCB-based therapeutics for anxiety-
related disorders.
METHODS
Drugs and Animals
Male, ICR mice (21–24g) were used in most experiments
(Harlan, Madison, WI). For one experiment, male wild-type
(WT, C57/BL6) and FAAH
 /  mice derived from homo-
zygous breeders were used (Cravatt et al, 2001). All animals
were housed on a 12:12 light/dark cycle with lights on at
0600. Animals had ad lib access to food and water. All
experiments were carried out in accordance with the NIH
Guide for the Use and Care of Laboratory Animals.
AM404 was purchased from Tocris Cookson (Ellisville,
MO). SR141716 and THC were provided by the NIDA Drug
Supply Program (Research Triangle Park, NC). CP55940
was a gift from Pfizer Central Research (Groton, CT).
URB597 was purchased from Cayman Chemical (Ann
Arbor, MI). All drugs, except URB597, were dissolved in
emulphor vehicle (18:1:1, saline:emulphor:ethanol), and
delivered by i.p. injection in a volume of 10ml/kg. URB597
was dissolved in DMSO and delivered in a volume of 50ml
by i.p. injection.
Restraint Procedure and Tissue Preparation
Animals were acclimated to the testing room 24h prior to
experimentation. Mice were restrained for 30min in
modified transparent 50ml plastic conical tubes with
numerous small air holes to increase ventilation; control
animals were left undisturbed in their home cage. One end
of the conical tube was closed using the screw top, while the
other end was removed and a tight gauze plug inserted after
the animals were placed inside. Animals were placed on the
bench top for the restraint period. Drugs were administered
at given times prior to restraint (see Figure 1 for schematic
depiction of experimental protocol). The direct CB1
receptor agonists THC (2.5mg/kg) and CP55940 (0.3mg/
kg) and the CB1 receptor antagonist SR141716 (5mg/kg)
were administered 30min prior to restraint. AM404 has low
affinity for CB1 receptors, but inhibits neuronal transport of
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donylglycerol (2-AG) (Beltramo et al, 1997; Beltramo and
Piomelli, 2000) and inhibits catabolism of AEA by fatty acid
amide hydrolase (FAAH) (Jarrahian et al, 2000). AM404
(10mg/kg) was administered 90min prior to restraint stress
to allow for the accumulation of extraneuronal eCBs
(Giuffrida et al, 2000). We administered the irreversible
FAAH inhibitor, URB597 (1mg/kg), 90min prior to
restraint, a time point at which brain AEA content is
elevated (Kathuria et al, 2003). We used a maximal dose of
URB597 to minimize the possibility of a false negative
result.
After 30min of restraint, animals were placed back in
their home cage for 2h, at which time they were
anesthetized with isoflurane, and perfused transcardially
with 10ml PBS, followed by 20ml of 4% formaldehyde.
After perfusion, brains were removed and incubated in 30%
sucrose for 48h. Frozen sections (35mm thick) were cut on a
cryostat and stored in an ethylene glycol solution at –201C
until processed for immunohistochemistry.
Fos Expression Studies
For quantitative studies, Fos-like immunoreactive (Fos-li)
neurons were detected using a rabbit anti-c-Fos antibody
(Oncogene, Cambridge, MA; 1:25000 dilution) and the
immunohistochemical protocol described previously (Patel
and Hillard, 2003). Sections were counterstained with
toluidine blue to assist with identification of amygdalar
subnuclei. For double-labeled anatomical studies, a goat
anti-c-Fos antibody (Santa Cruz Biotechnology, Santa Cruz,
CA; 1:1000 dilution) was used in combination with the
rabbit anti-CB1 antibody raised against the N-terminal
77-amino-acid residues of the CB1 receptor (Affinity Bio
Reagents, Golden, CO; 1:100 dilution) (Tsou et al,
1998). Reaction products for Fos and CB1 immunoreactivity
(CB1-ir) were visualized using appropriate biotin-conju-
gated secondary antibodies (1:500 dilution; Jackson
Immunoresearch, West Grove, PA) followed by processing
with the ABC kit (Vector Labs, Burlingame, CA) with Ni/Co
heavy metal intensification to yield a black nuclear reaction
product for Fos, and plain DAB to yield brown reaction
product for CB1-ir. For double-labeled fluorescence experi-
ments, a streptavidin-conjugated Alexa 488 (Molecular
Probes, Eugene, OR; 1:500 dilution) was used to yield a
fluorescent signal for Fos, while glutamic acid decarbox-
ylase 67 (GAD 67) immunoreactivity was detected using a
mouse anti-GAD 67 antibody (Chemicon, Temecula, CA;
1:2000 dilution), followed by 2h incubation in goat anti-
mouse CY3-conjugated secondary antibody (1:500 dilution;
Jackson Immunoresearch).
For quantitative analysis, bright-field photomicrographs
from matched coronal sections were obtained for each
region of interest using a Nikon Eclipse E600 microscope
and SPOT advanced imaging software (see Figure 2 for
schematic depiction of anatomical regions analyzed). All
sections from a given experiment were obtained during the
same microscopy session at which the light level and
camera exposure times were kept constant. This was
performed to minimize variability in the automated cell-
counting procedure. The numbers of Fos-li cells within the
BLA, MeA, and CeA were determined. A diagram depicting
the regions from which cell counts were obtained is shown
in Figure 2. Photomicrographs were opened in Image J
(available online from the NIH) for automated cell
counting. Images were converted to 8-bit mono, each
region (BLA, CeA, and MeA) was outlined with the freehand
draw tool, and the number of Fos-li nuclei was determined
within the specified region using the threshold and particle
analysis functions of Image J. Particles that met both optical
density and size requirements were automatically counted
as Fos-li.
vehicle-control and drug-control
vehicle-restraint and drug-restraint
Veh or AM404
        URB597
Veh or THC
            CP55940
            SR141716
Perfusion
Veh or AM404
         URB597
Veh or THC
            CP55940
            SR141716
Perfusion
-90  -30  0
150 min
30
Figure 1 Schematic diagram of experimental protocol used in drug
pretreatment studies. All experiments included four groups (n¼4–5/
group): vehicle-control (V-C), animals injected with vehicle at the same
pretreatment time as the appropriate drug and left in their home cage until
perfusion; drug-control (D-C), animals injected with drug and left in their
home cage until perfusion; vehicle-restraint (V-R); animals injected with
vehicle at the same pretreatment time as the appropriate drug, restrained
for 30min, and returned to their home cage for 2h, then perfused; drug-
restraint (D-R), animals treated with drug and exposed to restraint,
returned to their home cage for 2h, and then perfused. The black rectangle
represents restraint exposure. Specific drugs were administered at time
points prior to restraint as indicated.
Figure 2 Schematic diagram of the anatomical regions used for
automated cell counting. The BLA, MeA, and CeA were outlined as
shown using the freehand draw tool of Image J and separate cell counts
were obtained from each region.
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Since the number of Fos-li cells in control animals varied
somewhat between individual experiments, statistical ana-
lyses were confined to comparisons between control and
treated animals from the same experiment and immuno-
histochemical procedure. For each region, data were
analyzed by two-way ANOVA factoring restraint condition
(control or restrained) and drug treatment (vehicle or
drug). When significant main effects of restraint or drug
were observed, post hoc Dunnett’s test was applied to
determine significant differences from the vehicle-control
(V-C) group. For the SR141716 dose–response experiment,
data were analyzed by one-way ANOVA followed by post
hoc Dunnett’s test. A po0.05 was considered to be
significant throughout. Data are presented as mean7SEM
number of Fos-li neurons; individual data points are also
shown in all figures.
RESULTS
Anatomical Description of CB1 Receptors and
Restraint-Induced Fos Expression within
the Amygdala
CB1-ir was detected within the BLA, MeA, and CeA (Figure 3a
and b). Intensely stained CB1-positive fibers were observed
surrounding cell bodies within the BLA. High CB1 expressing
cells that colocalized with GAD 67 were also observed within
the BLA, indicating CB1 expression by GABAergic inter-
neurons (not shown). Low levels of cytoplasmic CB1 staining
were also observed within BLA pyramidal neurons (not
shown). Within the CeA, only light, diffuse staining was
observed, which appeared on very fine neuronal processes
(see Figure 3a). A similar pattern was observed in the MeA,
with the exception that occasionally, intensely labeled beaded
fibers were seen in this region (not shown). In general, this
description is almost identical to that observed using this
antibody in rats (Tsou et al, 1998), and similar to studies
using a C-terminal antibody in rats and mice (Katona et al,
2001); the major difference is the detection of immunor-
eactivity within the CeA using the N-terminal but not C-
terminal antibody. All staining was eliminated by removal of
primary antibody from the incubations.
To explore the interactions between environmental stress
and cannabinoids in the activation of the amygdala, we
utilized a threshold stimulus, 30min of restraint, in
combination with drug doses that produced little or no
effect on Fos expression alone. In general, 30min of
restraint consistently increased the number of Fos-li
neurons within the BLA and MeA, but not CeA (see Figure
3a and b, and below), indicating that the stimulus was
sufficient to increase BLA and MeA activity, but was not of
sufficient intensity or duration to increase CeA activity. The
distribution of restraint-induced Fos expression within the
amygdala can be seen in Figure 3a–c. Double-labeling
studies indicate that cells expressing Fos in response to
restraint stress within the BLA were not high CB1 expressing
(Figure 3b); however, Fos-li neurons within BLA were found
to receive perisomatic contacts from CB1-ir fibers (see
Figure 3b). Additional double-labeling studies indicate that
restraint did not induce Fos expression within GAD
Figure 3 Photomicrographs showing Fos expression within the BLA and
CeA in an animal exposed to 30min of restraint. Fos-li cells are visible as
black nuclei in (a) and (b), and as green nuclei in (c). (a) Double-stained
section showing CB1-ir (brown) and restraint-induced Fos expression
within the amygdala. Note the high density of CB1-ir fibers and high CB1
expressing cell bodies within the BLA, and the lower level of CB1-ir within
the CeA. (b) Higher magnification view of the BLA. Note the lack of
restraint-induced Fos expression within high CB1 expressing neurons, and
CB1-ir fibers forming perisomatic contacts onto Fos-li neurons. (c) Double-
stained section showing GAD 67 staining (red) and restraint-induced Fos
expression (green). Note the lack of Fos expression within GAD 67-
positive neurons. Bar represents approximately 200 mm in (a), 50 mm in (b),
and 100 mm in (c).
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data indicate that restraint induces Fos expression within
BLA pyramidal projection neurons, but not GABAergic
interneurons.
Effects of the CB1 Agonists THC and CP55940 on
Restraint-Induced Fos Expression
To determine whether there is an interaction between
environmental stress and CB1 receptor activation in the
regulation of amygdalar activation, the CB1 receptor
agonists THC (2.5mg/kg) and CP55940 (0.3mg/kg) were
administered 30min prior to restraint stress. Restraint
significantly increased the number of Fos-li cells within the
BLA in the THC experiment only. In the absence of
restraint, neither THC nor CP55940 significantly increased
the number of Fos-li cells within the BLA compared to
vehicle-treated control animals (Figures 4 and 5). Pretreat-
ment of mice with CP55940 or THC prior to restraint did
not significantly affect Fos expression within the BLA
compared to vehicle-pretreated restrained animals (Figures
4 and 5). For the THC experiment, two-way ANOVA
revealed a significant effect of drug treatment (F(1,14)¼4.93,
p¼0.043) and restraint (F(1,14)¼14.91, p¼0.0017) but no
interaction (F(1,14)¼0.61, p¼0.45, NS). For the CP55940
experiment, two-way ANOVA revealed a significant effect
of restraint (F(1,15)¼16.94, p¼0.0009) but not drug
(F(1,15)¼0.33, p¼0.58, NS), and no significant interaction
(F(1,15)¼3.70, p¼0.75, NS).
The effects of THC and CP55940 on restraint-induced Fos
expression within the MeA were also examined. Restraint
increased the number of Fos-li cells within the MeA,
whereas THC and CP55950 alone had no effect (Table 1).
Pretreatment with THC or CP55940 did not affect restraint-
induced Fos expression within the MeA (Table 1). For the
THC experiment, two-way ANOVA revealed a significant
effect of restraint (F(1,11)¼43.5, po0.0001) and drug
(F(1,11)¼7.3, p¼0.02), but no interaction (F(1,11)¼0.39,
p¼0.55, NS); for the CP55940 experiment, two-way
ANOVA revealed a significant effect of restraint
(F(1,16)¼208.7, po0.0001) but not drug (F(1,16)¼0.38,
p¼0.54, NS), and no interaction (F(1,16)¼2.7, p¼0.11, NS).
Restraint did not increase the number of Fos-li cells
within the CeA. In the absence of restraint, neither THC nor
CP55940 significantly increased the number of Fos-li cells
within the CeA compared to vehicle-treated control animals
(Figures 4 and 5). However, in contrast to the BLA and
MeA, pretreatment with THC or CP55940 significantly and
Figure 4 Interactions between THC (2.5mg/kg) and 30min restraint
stress in the expression of Fos within the BLA (a) and CeA (b). *po0.05,
**po0.01, significantly different from the V-C group. Note: some of the
Y-axes in subsequent figures use a different scale. Therefore, a dashed line
is shown at the 50-cell mark for easier comparison among experiments.
Figure 5 Interactions between CP55940 (0.3mg/kg) and 30min
restraint stress in the expression of Fos within the BLA (a) and CeA (b).
*po0.05, **po0.01, significantly different from the V-C group.
Table 1 Effects of THC (2.5mg/kg), CP55940 (0.3mg/kg),
AM404 (10mg/kg), and SR141716 (5mg/kg) on Restraint-Induced
Fos Expression within the MeA
V-C V-R D-C D-R
THC 1.570.86 22.471.7** 8.673.5 34.075.6**
CP55940 6.871.0 29.471.4** 5.071.1 33.472.8**
AM404 1.870.5 7.472.6* 2.070.6 9.873.0*
SR141716 1.070.4 13.472.8** 1.270.3 11.873.0**
All comparisons were made to brain slices assayed for c-Fos expression at the
same time. *po0.05, **po0.01; significantly different from the V-C group
(n¼4–5/group).
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in the CeA. For the THC experiment, two-way ANOVA
revealed a significant effect of restraint (F(1,14)¼14.33,
p¼0.002) and drug (F(1,14)¼28.8, po0.0001), and a
significant interaction (F(1,14)¼8.45, p¼0.011). For the
CP55940 experiment, two-way ANOVA revealed a signifi-
cant effect of restraint (F(1,15)¼15.11, p¼0.0015) and drug
(F(1,15)¼16.31, p¼0.0011), and a significant interaction
(F(1,15)¼11.46, p¼0.0041). Photomicrographs depicting the
synergistic interaction between CP55940 and restraint are
shown in Figure 6.
Effects of eCB Transport Inhibitor AM404
on Restraint-Induced Fos Expression
To explore whether eCBs contribute to stress-induced Fos
expression within the amygdala, the eCB transport inhibitor
AM404 was administered prior to restraint stress. Restraint
increased the number of Fos-li cells within the BLA, whereas
AM404 alone had no effect (Figure 7). Pretreatment of mice
with AM404 did not affect restraint-induced Fos expression
within the BLA. Two-way ANOVA revealed a significant
effect of restraint (F(1,15)¼19.28, po0.0001) but not drug
(F(1,15)¼1.64, p¼0.22, NS), and no significant interaction
(F(1,15)¼0.39, p¼0.54, NS).
The effects of AM404 on restraint-induced Fos expression
with the MeA were also examined. Restraint increased the
number of Fos-li cells within the MeA, whereas AM404
alone had no effect (Table 1). Pretreatment with AM404
did not affect restraint-induced Fos expression within the
MeA. Two-way ANOVA revealed a significant effect of
restraint (F(1,16)¼10.79, p¼0.0047) but not drug (F(1,16)
¼0.040, p¼0.53, NS), and no interaction (F(1,16)¼0.29,
p¼0.59, NS).
Neither restraint nor AM404 alone significantly increased
the number of Fos-li cells within the CeA. In contrast to the
BLA and MeA, pretreatment with AM404 significantly
potentiated restraint-induced Fos expression within the
CeA (Figure 7). Two-way ANOVA revealed a significant
effect of restraint (F(1,15)¼15.25, p¼0.0014) and drug
(F(1,15)¼14.18, p¼0.0019), and a significant interaction
(F(1,15)¼6.00, p¼0.027). Although these data indicate an
interaction between AM404 and restraint stress in the
induction of Fos, the magnitude of this effect was far less
than that seen with direct agonists. In addition, cells
expressing Fos in response to the combination of AM404
and restraint were restricted to the capsular division of
the CeA.
Effects of FAAH Inhibition on Restraint-Induced Fos
Expression
We determined whether pharmacological or genetic inhibi-
tion of FAAH activity interacted with restraint stress to
induce Fos expression within the amygdala. URB597 is not
soluble in the emulphor vehicle used in all other studies and
was therefore delivered in a small volume of DMSO.
Intraperitoneal administration of DMSO alone increased
Fos expression within the amygdala compared to emulphor-
injected animals, consistent with its caustic properties in
vivo. However, compared to vehicle-treated animals,
URB597 did not increase Fos expression within the BLA
Figure 6 Photomicrographs showing the interaction between CP55940
and restraint stress in the induction of Fos within the CeA. Note the robust
Fos induction in the CP-R group only.
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restraint-induced Fos expression within the BLA or CeA
(Figure 8). For the BLA, two-way ANOVA revealed a
significant effect of restraint (F(1,16)¼15.78, p¼0.0011) but
not drug (F(1,16)¼0.065, p¼0.80, NS), and no significant
interaction (F(1,16)¼1.77, p¼0.20, NS). For the CeA, two-
way ANOVA revealed no significant effect of restraint
(F(1,16)¼4.07, p¼0.061, NS) or drug (F(1,16)¼1.90, p¼
0.190, NS), and no significant interaction (F(1,16)¼0.078,
p¼0.783, NS).
Mice lacking FAAH exhibit elevated endogenous AEA,
but not 2-AG, levels, thus representing a genetic model of
enhanced AEA signaling (Cravatt et al, 2001). We compared
the effects of restraint stress on amygdalar Fos expression
between FAAH
 /  and WT mice. In accord with our
pharmacological data, no significant difference in restraint-
induced Fos expression within either the BLA or CeA was
observed between WT and FAAH
 /  mice (Figure 9). For
the BLA, two-way ANOVA revealed a significant effect of
restraint (F(1,12)¼13.51, p¼0.003) but not genotype
(F(1,12)¼1.20, p¼0.30, NS), and no interaction
(F(1,12)¼0.15, p¼0.710, NS). For the CeA, two-way ANOVA
revealed a significant effect of restraint (F(1,11)¼17.3,
p¼0.008) but not genotype (F(1,11)¼0.1, p¼0.81, NS),
and no interaction (F(1,11)¼0.41, p¼0.63, NS).
Effects of the CB1 Receptor Antagonist SR141716 on
Restraint-Induced Fos Expression
To explore whether tonic eCB signaling modulates amyg-
dalar activity, we treated mice with the CB1 receptor
antagonist SR141716 (5 and 10mg/kg) 2h before perfusion.
SR141716 produced a dose-dependent increase in Fos
expression within the BLA and CeA (Figure 10). For the
BLA, one-way ANOVA revealed a significant effect of
Figure 7 Interactions between AM404 (10mg/kg) and 30min restraint
stress in the expression of Fos within the BLA (a) and CeA (b). *po0.05,
**po0.01, significantly different from the V-C group.
Figure 8 Interactions between URB597 (1mg/kg) and 30min restraint
stress in the expression of Fos within the BLA (a) and CeA (b). *po0.05,
significantly different from the V-C group.
Figure 9 Effects of 30min restraint stress on Fos expression within the
BLA (a) and CeA (b) in WT and FAAH
 /  mice. *po0.05, significantly
different from the þ/þ C group. There was no significant effect of
genotype on restraint-induced Fos expression within the BLA or CeA.
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ANOVA revealed a significant effect of treatment
(F(2,12)¼29.36, po0.0001).
To determine whether there is an interaction between
restraint stress and eCB signaling, we pretreated animals
with the CB1 receptor antagonist SR141716 (5mg/kg)
30min prior to restraint. Restraint significantly increased
the number of Fos-li cells within the BLA and MeA, but not
CeA. SR141716 alone did not increase the number of Fos-li
cells within the BLA, MeA, or CeA. SR141716 pretreatment
significantly affected restraint-induced Fos expression with-
in the BLA but did not significantly affect restraint-induced
Fos expression within the CeA or MeA (Figure 11 and
Table 1). For the BLA, two-way ANOVA revealed a
significant effect of restraint (F(1,16)¼11.20, p¼0.004) but
not drug (F(1,16)¼0.003, p¼0.97, NS), and a significant
interaction (F(1,16)¼5.14, p¼0.037). For the CeA, two-way
ANOVA revealed a significant effect of restraint
(F(1,15)¼24.36, p¼0.0002) and drug (F(1,15)¼24.21,
p¼0.0002), but no significant interaction (F(1,15)¼2.80,
p¼0.11, NS). For the MeA, two-way ANOVA revealed a
significant effect of restraint (F(1,15)¼26.31, p¼0.0001) but
not drug (F(1,15)¼0.010, p¼0.76, NS), and no interaction
(F(1,15)¼0.16, p¼0.69, NS).
DISCUSSION
In order to detect a positive interaction between stress and
cannabinoids, efforts were made to choose a stressor that
produced a threshold level of Fos expression within the
amygdala. Based on preliminary studies, we utilized 30min
of restraint. This stimulus produced a consistent activation
of the BLA and MeA, but not CeA. Similarly, pilot dose–
response studies were used to select doses of drugs that
produced little, if any, activation of the amygdala. This
combination of stimuli resulted in the detection of
synergistic interactions between environmental stress and
CB1 receptor agonists in the activation of CeA, but not BLA
or MeA, as indexed by a robust induction of Fos protein.
Our data also indicate that augmentation of AEA signaling
is not sufficient to recapitulate the effects of direct CB1
agonists on Fos expression within the CeA, a finding that
could be relevant to the development of eCB-based
therapeutics for anxiety-related disorders. Lastly, our data
with SR141716 indicate that tonic CB1 receptor activation
inhibits amygdalar activity under nonstressed conditions.
In general, our data are consistent with the model
proposed by Katona et al (2001) that CB1 agonists inhibit
BLA GABAergic neurotransmission, which effectively re-
duces the threshold for activation of the BLA–CeA pathway
by salient sensory stimuli. First, consistent with previous
studies (Katona et al, 2001), CB1-ir neurons within the BLA
were found to be GABAergic, based on colocalization with
GAD 67, supporting the role of CB1 receptors in the
modulation of GABAergic transmission. Second, neurons
that expressed Fos in response to restraint were found to
receive perisomatic contacts from CB1-ir fibers, providing
an anatomical substrate which is consistent with an effect of
CB1 receptor activity on the activation of BLA neurons.
Third, our functional data indicate that threshold aversive
environmental stimuli induce robust activation of CeA
neurons when combined with threshold doses of direct CB1
receptor agonists. That blockade of CB1 receptors during
Figure 10 Effects of the CB1 receptor antagonist SR141716 (5 and
10mg/kg) on Fos expression within the BLA (a) and CeA (b). **po0.01,
significantly different from vehicle treatment.
Figure 11 Interactions between SR141716 (5mg/kg) and restraint stress
in the expression of Fos within the BLA (a) and CeA (b). **po0.01,
significantly different from the V-C group.
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in the BLA also supports this hypothesis. Since the restraint
responsive neurons within the BLA were determined to be
pyramidal projection neurons (based on a lack of coloca-
lization with the GABAergic neuronal marker GAD67), we
conclude that CB1 receptor activation decreases the thresh-
old at which salient stimuli activate the BLA–CeA pathway
in vivo.
However, one aspect of the model proposed by Katona
et al is not supported by the present results. The model
predicts that stress-induced neuronal activation in the BLA
should also be potentiated by CB1 receptor activation, a
finding not consistently observed in this study. Several
methodological and theoretical possibilities could account
for this difference. Methodological issues relate primarily to
the use of immediate early gene expression as a marker of
neuronal activation. It is possible that the activity of BLA
neurons is increased by the combination of cannabinoid
agonists and restraint, but the increase is not sufficient to
induce detectable Fos expression. Alternatively, neurons
that express Fos in response to restraint alone could be
more active when restraint is combined with cannabinoid
agonist administration, but since these cells would already
have been counted as Fos-li, no further increase in the
number of Fos-li neurons would be observed.
A more likely explanation is that the assumption of the
original model, that the sole site of action of the
cannabinoids is the BLA, is not correct. For example,
cannabinoid actions within the CeA itself could result in
potentiation of stress-induced activation of the CeA. This
hypothesis is supported by the presence of CB1 receptors
within the CeA (present data; see also Matsuda et al, 1993;
Tsou et al, 1998) and the ability of direct injections of THC
into CeA to induce anxiety responses in mice (Onaivi et al,
1995). Although the lack of effect of CB1 receptor activation
on GABAergic transmission within this region argues
against this possibility (Katona et al, 2001), the precise role
of CB1 receptor activation in the modulation of CeA
neuronal activity remains to be determined.
Another possibility is that CB1 agonist potentiation of
stress-induced CeA activation involves a trans-synaptic
mechanism. For example, GABAergic cells within inter-
calated cell masses (ICM), which lie at the anatomical
interface of the BLA and CeA, generate feedforward
inhibition of CeA neurons in response to BLA activation
(Royer et al, 1999, 2000), and are regulated by extrinsic
glutamatergic afferents from the prefrontal cortex and
dopaminergic afferents from the ventral midbrain (Bissiere
et al, 2003; Quirk et al, 2003). Therefore, cannabinoid
actions within these regions, which are known to occur
(French et al, 1997; Gessa et al, 1998; Auclair et al, 2000;
Patel and Hillard, 2003), could modulate CeA activity
independently of the BLA, via modulation of ICM neuronal
activity. Determining the contributions of these potential
mechanisms to the effects observed in this study remains an
important future goal.
Several issues regarding the pharmacological aspects of
the present study also warrant discussion. The in vivo
potency difference between THC and CP55940 in the
activation of Fos expression within the CeA (less than 10-
fold) is far less than that predicted by the differences in
binding affinity for CB1 receptors (about an 80-fold
difference) (Hillard et al, 1995). THC has lower efficacy at
CB1 receptor activation compared to CP55940 (Kearn et al,
1999), which further suggests that in vivo differences
between THC and CP55940 do not correlate with in vitro
pharmacological properties. It is possible that the high
affinity and efficacy of CP55940 result in robust receptor
internalization and desensitization (Hsieh et al, 1999). In
contrast, the relatively low affinity and efficacy of THC
could result in less internalization/desensitization and,
therefore, be more likely to support continuous receptor
signaling. The present data are at odds with those of Arnold
et al (2001) in which 0.25mg/kg CP55940 produced a robust
increase in CeA Fos expression in rats. By contrast, we
detected Fos expression within the CeA at 0.3mg/kg
CP55940 only when mice were also exposed to restraint.
The differences between these results could be attributed to
species used; alternatively, the present findings suggest that
the rats in the former study were stressed, in addition to
cannabinoid-treated. This notion is supported by the fact
that the rats in the former study were exposed to behavioral
tests and body temperature measurements before perfusion
for Fos immunohistochemistry.
We also explored whether augmentation of eCB content
interacted with restraint stress in the activation of the
amygdala. AM404, administered at a time and dose known
to increase AEA content in plasma (Giuffrida et al, 2000),
potentiated restraint-induced Fos expression within the
CeA, although the magnitude of this increase was far less
than that produced by direct CB1 receptor agonists. In
contrast, the FAAH inhibitor URB597, administered at a
time and dose shown to increase brain AEA content and
reduce FAAH activity (Kathuria et al, 2003), did not alter
restraint-induced Fos expression within the BLA or CeA. In
addition, FAAH
 /  mice, which exhibit highly elevated
brain AEA content (Cravatt et al, 2001), did not exhibit a
potentiated amygdalar response to restraint compared to
WT mice. Taken together, these data strongly suggest that
complete lack of FAAH activity, and the associated elevation
in AEA content, is not sufficient to mimic the effects of
direct CB1 agonists or AM404. This dissociation between
FAAH inhibition and CB1 receptor activation on restraint-
induced CeA activity could be relevant to the monophasic,
dose-dependent anxiolytic actions of URB597, compared to
the biphasic effects of direct cannabinoid agonists on
anxiety (Kathuria et al, 2003). Lastly, it is possible that the
selective interaction between AM404 and restraint stress,
compared to FAAH inhibition, arises from the ability of
AM404 to inhibit re-uptake of both AEA and 2-AG, since
neither URB597 (Kathuria et al, 2003) nor genetic deletion
of FAAH affects brain 2-AG content (unpublished data). In
other words, it is possible that the eCB that mediates the
effects of AM404 in this assay is 2-AG, not AEA. Another
possibility is that the effects of AM404 are mediated via
activation of vanilloid VR1 receptors, as it is an agonist of
these receptors (Lastres-Becker et al, 2003).
The effects of SR141716 on amygdalar neuronal activity
are paradoxical in the light of the effects of CB1 agonists.
SR141716 produced a dose-dependent increase in Fos
expression within the BLA and CeA, suggesting that eCB
tone suppresses amygdala activity, an effect observed within
other limbic regions such as the prefrontal cortex and
nucleus accumbens (Alonso et al, 1999; Duarte et al, 2004).
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SR141716 on amygdalar activation. First, since CB1 receptor
activation has been shown to decrease glutamatergic
transmission within the BLA (Azad et al, 2003),
SR141716-induced blockade of eCB tone could result in
increased glutamatergic transmission, activation of BLA
and, subsequently, CeA neurons. This suggestion, however,
is not supported by anatomical data, since asymmetrical
synapses within the BLA very rarely express CB1 receptors
detected using a C-terminal antibody (Katona et al, 2001).
Alternatively, since CB1 receptors are located on CCK-
positive interneurons within the BLA (McDonald and
Mascagni, 2001), and activation of CB1 receptors can inhibit
CCK release from hippocampal slices (Beinfeld and Con-
nolly, 2001), SR141716-induced blockade of eCB tone could
result in increased CCK release within the BLA. Since intra-
amygdala injections of CCK can induce anxiety-like
behaviors (Belcheva et al, 1994), and systemic administra-
tion of CCK increases Fos expression within the CeA (Day
et al, 1994), a CCK-dependent mechanism could subserve
the amygdala-activating effects of SR141716 in rodents.
In conclusion, our data clearly support a role for
increased CeA activity in the interactions between CB1
receptor agonists and environmental stress, and suggest
that eCB signaling tonically suppresses the activity of the
BLA–CeA pathway under nonstressed conditions. These
findings are generally consistent with the known cellular
effects of CB1 receptor activation within the amygdala. The
CeA integrates amygdalar, thalamic, cortical, and brainstem
inputs, and projects to limbic, hypothalamic, and auto-
nomic targets. Therefore, we suggest the CeA could be an
important neural substrate relevant to the context-depen-
dent autonomic, affective, and emotional effects of cannabis
intoxication in humans.
ACKNOWLEDGEMENTS
These studies were supported by National Institute of
Health Grants R01 DA016967 and F30 DA15575 (SP). We
thank Craig T Roelke for excellent technical assistance. We
also acknowledge the anonymous reviewer who suggested
that increased activity of the CeA could be relevant to the
anxiolytic properties of cannabinoids.
REFERENCES
Abel EL (1971). Changes in anxiety feelings following marihuana
smoking. the alternation in feelings of anxiety resulting from the
smoking of marihuana (Cannabis sativa L.). Br J Addict Alcohol
Other Drugs 66: 185–187.
Adams IB, Martin BR (1996). Cannabis: pharmacology and
toxicology in animals and humans. Addiction 91: 1585–1614.
Alonso R, Voutsinos B, Fournier M, Labie C, Steinberg R, Souilhac
J et al (1999). Blockade of cannabinoid receptors by SR141716
selectively increases Fos expression in rat mesocorticolimbic
areas via reduced dopamine D2 function. Neuroscience 91:
607–620.
Arnold JC, Topple AN, Mallet PE, Hunt GE, McGregor IS (2001).
The distribution of cannabinoid-induced Fos expression in rat
brain: differences between the Lewis and Wistar strain. Brain Res
921: 240–255.
Auclair N, Otani S, Soubrie P, Crepel F (2000). Cannabinoids
modulate synaptic strength and plasticity at glutamatergic
synapses of rat prefrontal cortex pyramidal neurons. J Neuro-
physiol 83: 3287–3293.
Azad SC, Eder M, Marsicano G, Lutz B, Zieglgansberger W,
Rammes G (2003). Activation of the cannabinoid receptor
type 1 decreases glutamatergic and GABAergic synaptic
transmission in the lateral amygdala of the mouse. Learn Mem
10: 116–128.
Beinfeld MC, Connolly K (2001). Activation of CB1 cannabinoid
receptors in rat hippocampal slices inhibits potassium-evoked
cholecystokinin release, a possible mechanism contributing to
the spatial memory defects produced by cannabinoids. Neurosci
Lett 301: 69–71.
Belcheva I, Belcheva S, Petkov VV, Petkov VD (1994). Asymmetry
in behavioral responses to cholecystokinin microinjected into
rat nucleus accumbens and amygdala. Neuropharmacology 33:
995–1002.
Beltramo M, Piomelli D (2000). Carrier-mediated transport and
enzymatic hydrolysis of the endogenous cannabinoid 2-arachi-
donylglycerol. Neuroreport 11: 1231–1235.
Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A,
Piomelli D (1997). Functional role of high-affinity anandamide
transport, as revealed by selective inhibition. Science 277:
1094–1097.
Berrendero F, Maldonado R (2002). Involvement of the opioid
system in the anxiolytic-like effects induced by Delta(9)-
tetrahydrocannabinol. Psychopharmacology (Berl) 163: 111–117.
Bissiere S, Humeau Y, Luthi A (2003). Dopamine gates LTP
induction in lateral amygdala by suppressing feedforward
inhibition. Nat Neurosci 6: 587–592.
Carlin AS, Bakker CB, Halpern L, Post RD (1972). Social
facilitation of marijuana intoxication: impact of social set and
pharmacological activity. J Abnorm Psychol 80: 132–140.
Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK,
Martin BR et al (2001). Supersensitivity to anandamide
and enhanced endogenous cannabinoid signaling in mice
lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 98:
9371–9376.
Davis M (2002). Neural circuitry of anxiety and stress disorders.
In: Davis KL, Charney D, Coyle JT, Nemeroff C (eds).
Neuropsychopharmacology: The Fifth Generation of Progress.
American College of Neuropsychopharmacology: Philadelphia,
PA. pp 931–951.
Day HE, McKnight AT, Poat JA, Hughes J (1994). Evidence that
cholecystokinin induces immediate early gene expression in the
brainstem, hypothalamus and amygdala of the rat by a CCKA
receptor mechanism. Neuropharmacology 33: 719–727.
Degenhardt L, Hall W, Lynskey M (2001). The relationship
between cannabis use, depression and anxiety among Australian
adults: findings from the National Survey of Mental Health and
Well-Being. Soc Psychiatry Psychiatr Epidemiol 36: 219–227.
Duarte C, Alonso R, Bichet N, Cohen C, Soubrie P, Thiebot MH
(2004). Blockade by the cannabinoid CB1 receptor antagonist,
rimonabant (SR141716), of the potentiation by quinelorane of
food-primed reinstatement of food-seeking behavior. Neuropsy-
chopharmacology 29: 911–920.
French ED, Dillon K, Wu X (1997). Cannabinoids excite dopamine
neurons in the ventral tegmentum and substantia nigra.
Neuroreport 8: 649–652.
Gessa GL, Melis M, Muntoni AL, Diana M (1998). Cannabinoids
activate mesolimbic dopamine neurons by an action on
cannabinoid CB1 receptors. Eur J Pharmacol 341: 39–44.
Giuffrida A, Rodriguez de Fonseca F, Nava F, Loubet-Lescoulie P,
Piomelli D (2000). Elevated circulating levels of anandamide
after administration of the transport inhibitor, AM404. Eur J
Pharmacol 408: 161–168.
Giuliani D, Ferrari F, Ottani A (2000). The cannabinoid agonist HU
210 modifies rat behavioural responses to novelty and stress.
Pharmacol Res 41: 47–53.
Cannabinoids, stress, and amygdala activation
S Patel et al
506
NeuropsychopharmacologyGregg JM, Small EW, Moore R, Raft D, Toomey TC (1976).
Emotional response to intravenous delta9tetrahydrocannabinol
during oral surgery. J Oral Surg 34: 301–313.
Hillard CJ, Edgemond WS, Campbell WB (1995). Characterization
of ligand binding to the cannabinoid receptor of rat brain
membranes using a novel method: application to anandamide.
J Neurochem 64: 677–683.
Hsieh C, Brown S, Derleth C, Mackie K (1999). Internalization
and recycling of the CB1 cannabinoid receptor. J Neurochem 73:
493–501.
Jarrahian A, Manna S, Edgemond WS, Campbell WB, Hillard CJ
(2000). Structure–activity relationships among N-arachidony-
lethanolamine (Anandamide) head group analogues for the
anandamide transporter. J Neurochem 74: 2597–2606.
Jones RT (1971). Marihuana-induced ‘high’: influence of expecta-
tion, setting and previous drug experience. Pharmacol Rev 23:
359–369.
Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A et al
(2003). Modulation of anxiety through blockade of anandamide
hydrolysis. Nat Med 9: 76–81.
Katona I, Rancz EA, Acsady L, Ledent C, Mackie K, Hajos N et al
(2001). Distribution of CB1 cannabinoid receptors in the
amygdala and their role in the control of GABAergic transmis-
sion. J Neurosci 21: 9506–9518.
Kearn CS, Greenberg MJ, DiCamelli R, Kurzawa K, Hillard CJ
(1999). Relationships between ligand affinities for the cerebellar
cannabinoid receptor CB1 and the induction of GDP/GTP
exchange. J Neurochem 72: 2379–2387.
Lastres-Becker I, de Miguel R, De Petrocellis L, Makriyannis A, Di
Marzo V, Fernandez-Ruiz J (2003). Compounds acting at the
endocannabinoid and/or endovanilloid systems reduce hyperki-
nesia in a rat model of Huntington’s disease. J Neurochem 84:
1097–1109.
MacLean KI, Littleton JM (1977). Environmental stress as a factor
in the response of rat brain catecholamine metabolism to delta8-
tetrahydrocannabinol. Eur J Pharmacol 41: 171–182.
Manzanares J, Corchero J, Fuentes JA (1999). Opioid and
cannabinoid receptor-mediated regulation of the increase in
adrenocorticotropin hormone and corticosterone plasma con-
centrations induced by central administration of delta(9)-
tetrahydrocannabinol in rats. Brain Res 839: 173–179.
Marin S, Marco E, Biscaia M, Fernandez B, Rubio M, Guaza C et al
(2003). Involvement of the kappa-opioid receptor in the
anxiogenic-like effect of CP 55,940 in male rats. Pharmacol
Biochem Behav 74: 649–656.
Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio
MG et al (2002). The endogenous cannabinoid system controls
extinction of aversive memories. Nature 418: 530–534.
Matsuda LA, Bonner TI, Lolait SJ (1993). Localization of cannabinoid
receptor mRNA in rat brain. J Comp Neurol 327: 535–550.
McDonald AJ, Mascagni F (2001). Localization of the CB1 type
cannabinoid receptor in the rat basolateral amygdala: high
concentrations in a subpopulation of cholecystokinin-containing
interneurons. Neuroscience 107: 641–652.
McGregor IS, Arnold JC, Weber MF, Topple AN, Hunt GE (1998).
A comparison of delta 9-THC and anandamide induced c-fos
expression in the rat forebrain. Brain Res 802: 19–26.
Naliboff BD, Rickles WH, Cohen MJ, Naimark RS (1976). Interac-
tions of marijuana and induced stress: forearm blood flow, heart
rate, and skin conductance. Psychophysiology 13: 517–522.
Ng LK, Lamprecht F, Williams RB, Kopin IJ (1973). Delta 9-
tetrahydrocannabinol and ethanol: differential effects on sympa-
thetic activity in differing environmental setting. Science 180:
1368–1369.
Onaivi ES, Chakrabarti A, Gwebu ET, Chaudhuri G (1995).
Neurobehavioral effects of delta 9-THC and cannabinoid (CB1)
receptor gene expression in mice. Behav Brain Res 72: 115–125.
Pare D, Royer S, Smith Y, Lang EJ (2003). Contextual inhibitory
gating of impulse traffic in the intra-amygdaloid network. Ann
NY Acad Sci 985: 78–91.
Patel S, Hillard CJ (2003). Cannabinoid-induced Fos expression
within A10 dopaminergic neurons. Brain Res 963: 15–25.
Quirk GJ, Gehlert DR (2003). Inhibition of the amygdala: key to
pathological states? Ann NY Acad Sci 985: 263–272.
Quirk GJ, Likhtik E, Pelletier JG, Pare D (2003). Stimulation of
medial prefrontal cortex decreases the responsiveness of central
amygdala output neurons. J Neurosci 23: 8800–8807.
Reilly D, Didcott P, Swift W, Hall W (1998). Long-term cannabis
use: characteristics of users in an Australian rural area.
Addiction 93: 837–846.
Royer S, Martina M, Pare D (1999). An inhibitory interface gates
impulse traffic between the input and output stations of the
amygdala. J Neurosci 19: 10575–10583.
Royer S, Martina M, Pare D (2000). Polarized synaptic interactions
between intercalated neurons of the amygdala. J Neurophysiol 83:
3509–3518.
Sah P, Faber ES, Lopez De Armentia M, Power J (2003). The
amygdaloid complex: anatomy and physiology. Physiol Rev 83:
803–834.
Szuster RR, Pontius EB, Campos PE (1988). Marijuana sensitivity
and panic anxiety. J Clin Psychiatry 49: 427–429.
Thomas H (1996). A community survey of adverse effects of
cannabis use. Drug Alcohol Depend 42: 201–207.
Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM (1998).
Immunohistochemical distribution of cannabinoid CB1 recep-
tors in the rat central nervous system. Neuroscience 83: 393–411.
Cannabinoids, stress, and amygdala activation
S Patel et al
507
Neuropsychopharmacology